Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 15 | 2022 | 794 | 3.370 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2020 | 638 | 2.650 |
Why?
|
| Receptors, Calcitriol | 4 | 2020 | 59 | 2.510 |
Why?
|
| Breast Neoplasms | 13 | 2021 | 1426 | 1.480 |
Why?
|
| MicroRNAs | 3 | 2023 | 386 | 1.310 |
Why?
|
| Naphthoquinones | 5 | 2020 | 35 | 1.270 |
Why?
|
| Prognosis | 8 | 2021 | 707 | 1.100 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2020 | 528 | 1.030 |
Why?
|
| Vitamin D | 3 | 2022 | 176 | 0.810 |
Why?
|
| Sunbathing | 1 | 2020 | 6 | 0.790 |
Why?
|
| Ultraviolet Rays | 2 | 2020 | 116 | 0.770 |
Why?
|
| Promoter Regions, Genetic | 4 | 2020 | 484 | 0.740 |
Why?
|
| Humans | 41 | 2023 | 34853 | 0.670 |
Why?
|
| Middle Aged | 21 | 2021 | 9642 | 0.660 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 16 | 0.660 |
Why?
|
| GTPase-Activating Proteins | 1 | 2018 | 26 | 0.650 |
Why?
|
| Chromosome Mapping | 1 | 2018 | 159 | 0.640 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 781 | 0.640 |
Why?
|
| Prostate-Specific Antigen | 2 | 2015 | 95 | 0.620 |
Why?
|
| Aged | 15 | 2021 | 6448 | 0.610 |
Why?
|
| Antineoplastic Agents | 3 | 2010 | 756 | 0.600 |
Why?
|
| Case-Control Studies | 7 | 2020 | 1056 | 0.590 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 430 | 0.580 |
Why?
|
| Carrier Proteins | 2 | 2015 | 287 | 0.560 |
Why?
|
| Apoptosis | 6 | 2020 | 1317 | 0.560 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 406 | 0.540 |
Why?
|
| Zanthoxylum | 1 | 2015 | 4 | 0.530 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 33 | 0.530 |
Why?
|
| Metabolomics | 1 | 2014 | 76 | 0.490 |
Why?
|
| Age Factors | 1 | 2017 | 1007 | 0.490 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2018 | 32 | 0.480 |
Why?
|
| Male | 16 | 2022 | 18870 | 0.460 |
Why?
|
| Plant Extracts | 1 | 2015 | 250 | 0.430 |
Why?
|
| Cell Proliferation | 4 | 2021 | 1149 | 0.420 |
Why?
|
| Female | 22 | 2023 | 19873 | 0.420 |
Why?
|
| Androgens | 2 | 2011 | 87 | 0.390 |
Why?
|
| BRCA2 Protein | 2 | 2017 | 37 | 0.380 |
Why?
|
| Receptor, erbB-2 | 3 | 2021 | 122 | 0.370 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 16 | 0.370 |
Why?
|
| RNA, Messenger | 3 | 2021 | 1152 | 0.360 |
Why?
|
| Benzamides | 1 | 2010 | 76 | 0.350 |
Why?
|
| Adult | 12 | 2021 | 11034 | 0.350 |
Why?
|
| Cell Line, Tumor | 10 | 2021 | 2128 | 0.330 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2008 | 3 | 0.330 |
Why?
|
| Gentamicins | 1 | 2008 | 9 | 0.320 |
Why?
|
| Complement Activation | 1 | 2008 | 13 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 52 | 0.320 |
Why?
|
| Risk | 3 | 2015 | 256 | 0.280 |
Why?
|
| Cell Cycle | 5 | 2018 | 309 | 0.280 |
Why?
|
| Mutation | 2 | 2017 | 1023 | 0.280 |
Why?
|
| Escherichia coli | 1 | 2008 | 436 | 0.260 |
Why?
|
| Receptors, Progesterone | 3 | 2018 | 78 | 0.250 |
Why?
|
| Receptors, Estrogen | 3 | 2018 | 145 | 0.240 |
Why?
|
| Immunohistochemistry | 3 | 2022 | 859 | 0.230 |
Why?
|
| Cell Survival | 6 | 2020 | 818 | 0.220 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 600 | 0.220 |
Why?
|
| Blotting, Western | 3 | 2010 | 834 | 0.210 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 86 | 0.210 |
Why?
|
| beta-Crystallin B Chain | 1 | 2021 | 2 | 0.210 |
Why?
|
| RNA, Neoplasm | 1 | 2021 | 25 | 0.210 |
Why?
|
| Genotype | 4 | 2020 | 641 | 0.200 |
Why?
|
| ROC Curve | 1 | 2021 | 138 | 0.200 |
Why?
|
| Haplotypes | 3 | 2020 | 152 | 0.200 |
Why?
|
| Tamoxifen | 1 | 2020 | 61 | 0.190 |
Why?
|
| RNA Interference | 1 | 2021 | 225 | 0.190 |
Why?
|
| Phosphoproteins | 1 | 2021 | 154 | 0.190 |
Why?
|
| Histones | 1 | 2021 | 177 | 0.190 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 145 | 0.180 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 303 | 0.180 |
Why?
|
| DNA Methylation | 2 | 2018 | 301 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2018 | 184 | 0.180 |
Why?
|
| Interleukin-10 | 1 | 2020 | 69 | 0.180 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 203 | 0.180 |
Why?
|
| Risk Factors | 4 | 2020 | 3414 | 0.170 |
Why?
|
| Computational Biology | 1 | 2021 | 275 | 0.170 |
Why?
|
| Up-Regulation | 1 | 2021 | 490 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 247 | 0.170 |
Why?
|
| Cyclins | 1 | 2018 | 35 | 0.160 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2018 | 42 | 0.160 |
Why?
|
| Gene Amplification | 1 | 2018 | 24 | 0.160 |
Why?
|
| Oxidation-Reduction | 2 | 2021 | 407 | 0.160 |
Why?
|
| Microfluidics | 1 | 2018 | 39 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 53 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 114 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 47 | 0.150 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2020 | 81 | 0.150 |
Why?
|
| Flow Cytometry | 2 | 2009 | 392 | 0.150 |
Why?
|
| Isoquinolines | 2 | 2007 | 40 | 0.140 |
Why?
|
| Social Class | 1 | 2018 | 228 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 239 | 0.140 |
Why?
|
| Ditiocarb | 1 | 2015 | 4 | 0.140 |
Why?
|
| Emetine | 1 | 2015 | 13 | 0.140 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2015 | 5 | 0.140 |
Why?
|
| United States | 4 | 2017 | 3894 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 178 | 0.130 |
Why?
|
| Suntan | 1 | 2014 | 5 | 0.130 |
Why?
|
| Dipeptides | 1 | 2014 | 29 | 0.130 |
Why?
|
| NAD | 1 | 2014 | 39 | 0.130 |
Why?
|
| Phytotherapy | 1 | 2015 | 62 | 0.130 |
Why?
|
| Methylation | 1 | 2014 | 102 | 0.130 |
Why?
|
| Metabolome | 1 | 2014 | 47 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 65 | 0.120 |
Why?
|
| Myoblasts | 1 | 2014 | 25 | 0.120 |
Why?
|
| Osteopontin | 1 | 2014 | 35 | 0.120 |
Why?
|
| Nicotine | 2 | 2007 | 238 | 0.120 |
Why?
|
| Amino Acids | 1 | 2014 | 139 | 0.120 |
Why?
|
| Glutathione | 1 | 2014 | 160 | 0.120 |
Why?
|
| Genes, BRCA1 | 1 | 2013 | 13 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2014 | 160 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 64 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 165 | 0.110 |
Why?
|
| Smoking | 1 | 2020 | 903 | 0.110 |
Why?
|
| Plant Roots | 1 | 2015 | 153 | 0.110 |
Why?
|
| Alleles | 3 | 2020 | 284 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 257 | 0.100 |
Why?
|
| Benzoxazoles | 1 | 2011 | 9 | 0.100 |
Why?
|
| Oxazoles | 1 | 2011 | 19 | 0.100 |
Why?
|
| Age of Onset | 2 | 2017 | 98 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 605 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 2333 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 105 | 0.090 |
Why?
|
| Gene Dosage | 1 | 2009 | 74 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 52 | 0.090 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 8 | 0.090 |
Why?
|
| Neurotoxins | 2 | 2007 | 52 | 0.090 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 56 | 0.090 |
Why?
|
| Cell Death | 3 | 2021 | 260 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 480 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 445 | 0.080 |
Why?
|
| Complement C5b | 1 | 2008 | 1 | 0.080 |
Why?
|
| Complement Pathway, Classical | 1 | 2008 | 2 | 0.080 |
Why?
|
| Complement System Proteins | 1 | 2008 | 21 | 0.080 |
Why?
|
| Colony Count, Microbial | 1 | 2008 | 66 | 0.080 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 27 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 75 | 0.070 |
Why?
|
| Tissue Array Analysis | 2 | 2018 | 65 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 964 | 0.060 |
Why?
|
| Breast Neoplasms, Male | 1 | 2003 | 2 | 0.060 |
Why?
|
| Frameshift Mutation | 1 | 2003 | 6 | 0.060 |
Why?
|
| Pedigree | 1 | 2003 | 64 | 0.060 |
Why?
|
| Heterozygote | 1 | 2003 | 91 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2003 | 87 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 122 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2003 | 80 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2005 | 231 | 0.060 |
Why?
|
| Genomics | 1 | 2023 | 201 | 0.050 |
Why?
|
| Cell Nucleolus | 1 | 2021 | 9 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2021 | 52 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2021 | 114 | 0.050 |
Why?
|
| Aptamers, Nucleotide | 1 | 2021 | 28 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2003 | 328 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 74 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2020 | 171 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 92 | 0.040 |
Why?
|
| Mice | 2 | 2021 | 5668 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2018 | 9 | 0.040 |
Why?
|
| Osteonectin | 1 | 2018 | 7 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2018 | 25 | 0.040 |
Why?
|
| Cell Size | 1 | 2018 | 42 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 416 | 0.040 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 32 | 0.040 |
Why?
|
| Cadherins | 1 | 2018 | 82 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2018 | 118 | 0.040 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2018 | 68 | 0.040 |
Why?
|
| District of Columbia | 1 | 2018 | 68 | 0.040 |
Why?
|
| Rabbits | 1 | 2018 | 278 | 0.040 |
Why?
|
| Prevalence | 2 | 2017 | 1425 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 89 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 269 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 36 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 322 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 727 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 282 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 245 | 0.040 |
Why?
|
| Survival Rate | 1 | 2017 | 310 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 330 | 0.030 |
Why?
|
| Neuroblastoma | 2 | 2007 | 128 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 4012 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 569 | 0.030 |
Why?
|
| Sunlight | 1 | 2014 | 46 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 2014 | 21 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1349 | 0.030 |
Why?
|
| Animals | 2 | 2021 | 14307 | 0.030 |
Why?
|
| New York | 1 | 2013 | 69 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 111 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2021 | 1802 | 0.030 |
Why?
|
| Estrogens | 1 | 2014 | 190 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 423 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2018 | 1961 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 550 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 639 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 468 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 237 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 435 | 0.020 |
Why?
|
| Cell Line | 1 | 2014 | 1289 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 17 | 0.020 |
Why?
|
| Oncogenes | 1 | 2009 | 43 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 577 | 0.020 |
Why?
|
| Exercise | 1 | 2014 | 524 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 298 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2007 | 24 | 0.020 |
Why?
|
| Parkinsonian Disorders | 1 | 2007 | 35 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 580 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2005 | 36 | 0.020 |
Why?
|
| Conotoxins | 1 | 2005 | 18 | 0.020 |
Why?
|
| Thiazoles | 1 | 2005 | 71 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2005 | 137 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2004 | 429 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 984 | 0.010 |
Why?
|